ResMed Inc. announced its financial results for the first quarter of fiscal year 2027 ended September 30, 2026. The company ...
"During the first quarter of our fiscal year 2027, we delivered another strong set of results. 7% revenue growth on a core constant currency basis on the top line, 50 basis points of year-over-year ...
<?xml encoding="utf-8" ?> ResMed RMD reported first-quarter financial results on Thursday. The transcript from the company’s ...
ResMed Inc. ha presentado los resultados correspondientes al primer trimestre cerrado el 30 de septiembre de 2026. Durante ...
21:58 ResMed eleva su beneficio ajustado y sus ingresos en el primer trimestre fiscal MT 21:20 Flash de resultados (RMD): ...
ResMed Inc. hat seine Ergebnisse für das erste Quartal zum 30. September 2026 veröffentlicht. Im ersten Quartal erzielte das ...
ResMed Inc. heeft de resultaten over het eerste kwartaal eindigend op 30 september 2026 bekendgemaakt. In het eerste kwartaal ...
ResMed, Inc. è specializzata nella progettazione, produzione e commercializzazione di prodotti per la diagnosi, il trattamento e la gestione dei disturbi respiratori (principalme ...
ResMed ha registrato utili per azione non-GAAP pari a 2,91 USD nel primo trimestre dell'esercizio, rispetto ai 2,55 USD dello ...
Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basisQ1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP ...
ResMed reported first-quarter fiscal 2027 results with revenue of $1.4 billion, up 6% year-over-year and 7% on a core constant currency ...
Resmed Inc. Reports Q1 Revenue $1.41B, vs. FactSet Est of $1.39B MT 04:19pm Earnings Flash (RMD) Resmed Inc. Posts Q1 Adjusted EPS $2.91 per Share, vs. FactSet Est of $2.69 MT 02:19pm Drowsy Digital, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results